Prostate cancer burden in Central and South America  by Sierra, Mónica S. et al.
Cancer Epidemiology 44S (2016) S131–S140Prostate cancer burden in Central and South America$
Mónica S. Sierra*, Isabelle Soerjomataram, David Forman
International Agency for Research on Cancer, Section of Cancer Surveillance, France
A R T I C L E I N F O
Article history:
Received 21 January 2016
Received in revised form 24 May 2016
Accepted 27 June 2016
Keywords:
Prostate
Neoplasm
Screening
Central and South America
A B S T R A C T
Rationale and objective: The incidence of prostate cancer has increased in Central and South America
(CSA) in the last few decades. We describe the geographical patterns and trends of prostate cancer in CSA.
Methods: We obtained regional and national-level cancer incidence data from 48 population-based
registries in 13 countries and nation-wide cancer deaths from the WHO mortality database for
18 countries. We estimated world population age-standardized incidence (ASR) and mortality (ASMR)
rates per 100,000 person-years for 2003–2007 and the estimated annual percent change (EAPC) to
describe time trends.
Results: Prostate cancer was the most common cancer diagnosis and one of the leading causes of cancer
deaths among males in most CSA countries. From 2003–2007, ASRs varied between countries (6-fold) and
within countries (Brazil: 3–6-fold). French Guyana (147.1) and Brazil (91.4) had the highest ASRs whereas
Mexico (28.9) and Cuba (24.3) had the lowest. ASMRs varied by 4-fold. Belize, Uruguay and Cuba (24.1–
28.9) had the highest ASMRs while Peru, Nicaragua, and El Salvador (6.8–9.7) had the lowest. In
Argentina, Brazil, Chile and Costa Rica prostate cancer incidence increased by 2.8–4.8% annually whereas
mortality remained stable between 1997 and 2008.
Conclusion: The geographic and temporal variation of prostate cancer rates observed in CSA may in part
reﬂect differences in diagnostic and registration practices, healthcare access, treatment and death
certiﬁcation, and public awareness. The incidence of prostate cancer is expected to increase given recent
early detection activities and increased public awareness; however, the impact of these factors on
mortality remains to be elucidated.
ã 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd. This is an open access article
under the CC BY-NC-ND IGO 3.0 license (https://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
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Prostate cancer is the second most frequently diagnosed cancer
and the ﬁfth leading cause of cancer death among males
worldwide. In 2012, more than 1.1 million new prostate cancer
cases and 307,000 deaths were estimated globally, representing
15% of all new cancer diagnosis and 6.6% of all cancer-related
deaths [1]. There is a 25-fold geographic variation in the incidence
of prostate cancer across the world, with the highest rates seen in
high income countries in northern and western Europe, North$ This is an Open Access article published under the CC BY NC ND 3.0 IGO license
which permits users to download and share the article for non-commercial
purposes, so long as the article is reproduced in the whole without changes, and
provided the original source is properly cited. This article shall not be used or
reproduced in association with the promotion of commercial products, services or
any entity. There should be no suggestion that IARC endorses any speciﬁc
organisation, products or services. The use of the IARC logo is not permitted. This
notice should be preserved along with the article’s original URL.
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creativecommons.org/licenses/by-nc-nd/3.0/igo/).America and the Oceania [2]. Globally there has been a sustained
increase in prostate cancer incidence since the 1960s, with the
largest increase occurring in the late 1980s and early 1990s; due to
detection of asymptomatic disease. In many high income
countries, the incidence of prostate cancer has started to level
off after the rapid increases experienced between the 1980s
and1990s [3]; however, it continues to increase in countries in
transition [2]. The worldwide variation of prostate cancer
incidence rates and trends largely reﬂects differences in the use
of prostate speciﬁc antigen (PSA) testing [2–5]. In Argentina, Chile,
Costa Rica, Mexico, the United States, Canada, the United Kingdom,
Australia, and some European countries, prostate cancer mortality
rates have slightly declined since the 1990s [6–16]; while in Brazil,
Colombia, Cuba and Ecuador rates have steadily increased from
1980 to 2010 [6]. Declines in prostate cancer mortality may be
related to improvements in treatment and early detection;
however, the impact of prostate cancer screening in reducing
mortality remains a subject of considerable debate [2,7–14,16].
Although the etiology of prostate cancer remains poorly
understood, known determinants for the development of prostate
cancer are age, family history and race/ethnicity [2]. As with many. This is an open access article under the CC BY-NC-ND IGO 3.0 license (https://
S132 M.S. Sierra et al. / Cancer Epidemiology 44S (2016) S131–S140other cancers, age is strongly associated with an increased risk of
prostate cancer. Family history of prostate cancer has been
consistently associated with an increased risk of prostate cancer,
and the risk varies according to the degree of the relationship, the
number of relatives affected, and the age of diagnosis [17–20].
Although it is possible that increased early detection activities and
increased awareness among men with a family history of prostate
cancer could, in part, explain this positive association [17].
African populations and their descendants have a higher
incidence of prostate cancer than other ethnic/racial groups
[21,22]; although the reasons for this are still unclear, genetic
factors may explain this disparity [3,21–23]. While some studies
conducted in Central and South America (CSA) have shown a
higher prevalence of prostate cancer among Afro-descendants in
Guyana [24] and in Mulatto (mix between African and Caucasian
descendants) and Black men in Brazil [25,26] when compared to
other groups, other studies conducted in Brazil showed no
differences in the prevalence of prostate cancer between racial/
ethnic groups [27–30].
The CSA region has undergone a rapid epidemiologic and
nutritional transition and prostate cancer rates have concomitant-
ly increased [31–34]. In 2008, prostate cancer was the main cause
in loss of disability-adjusted life-years in Latin America (including
the Caribbean) [35]. In 2012, approximately 134,000 new cancer
cases and 43,000 cancer deaths were estimated to have occurred in
CSA, accounting for 12% of all cancer diagnoses and 14% of all
cancer deaths among males [1]. By the year 2030, the burden from
prostate cancer is expected to nearly double (249,000 new cases
and 86,000 deaths) in CSA, entirely due to the growth and aging of
the population [1]. Therefore, monitoring the burden of prostate
cancer in the region is of increasing importance. In this study we
describe the geographical patterns and trends of prostate cancer in
the CSA region, review the current public health policies and early
detection activities, and discuss our results in relation to their
impact on the incidence and mortality rates.
2. Methods
The present analysis includes prostate cancer (C61), as coded by
the 10th edition of the International Classiﬁcation of Diseases for
Oncology (ICD-10). The data sources and methods are described in
detail in an earlier article in this issue. In brief, we obtained
regional and national-level incidence data from 48 population-
based cancer registries in 13 countries and cancer deaths from the
World Health Organization mortality database for 18 countries. We
estimated age-standardized incidence (ASR) and mortality (ASMR)
rates per 100,000 person-years using the direct method and the
World standard population [36,37]. We estimated national ASRs by
aggregating the data from the available cancer registries using a
weighted average of local rates. Registries that provided formal
consent to use data by individual year of diagnosis for 10-years
were included in the time-trend analysis (Table 1). To describe
incidence and mortality time trends, we calculated the estimated
annual percent change (EAPC) for the most recent 10-year period
using the method proposed by Esteve et al. [38]. All of the EAPCs
were tested for equality to zero by using the corresponding
standard errors. We considered EAPCs statistically signiﬁcant if theTable 1
Countries included in the analysis of time trends.
Country Name of registries included 
Argentina Bahia Blanca 
Brazil Aracaju, Fortaleza, Goiania, Sao Paulo 
Chile Valdivia 
Costa Rica National registry p-value  0.05. We conducted all analyses in Stata version 12.1
(StataCorp) [39].
In addition, we estimated ASRs by registry location in order to
show within country variation. We also reviewed the current
public health policies within the pertinent country’s Ministry of
Health websites and conducted a literature review in PubMed to
identify prevention activities for prostate cancer in CSA. The
following MeSH key terms were used for the review: prostate
cancer, PSA, screening, early detection, Latin America, Central and
South America.
3. Results
3.1. Incidence and mortality
Table 2 shows age-standardized incidence and mortality rates
by country and period. During the most recent period evaluated,
prostate cancer was the most common malignancy diagnosed
among males in the CSA region, except in El Salvador and Cuba
where it ranked second (after stomach and lung, respectively).
During the most recent 5-year period (i.e. 2003–2007), the
incidence of prostate cancer varied by 6-fold across CSA countries.
The highest ASRs were observed in French Guyana (147.1) and
Brazil (91.4) and the lowest were in Mexico (28.9) and Cuba (24.3).
Prostate cancer was one of the two leading causes of cancer
deaths in males in Central and South America, except in Chile,
Argentina, Colombia and El Salvador where it ranked third.
Mortality rates varied by 4-fold, with the highest rates seen in
Belize (28.9), Uruguay (21.8), and Cuba (24.1) and the lowest in
Peru, Nicaragua, and El Salvador (rates between 6.8–9.7).
3.2. Within country incidence variations
Fig. 1 shows the incidence of prostate cancer in selected cancer
registry populations across Central and South America, with
corresponding 95% conﬁdence intervals. During the most recent 5-
year period, prostate cancer incidence varied from 1.2 to 2.6-fold in
countries with two or more registries, except in Brazil (incidence
rates varied from 2.8 to 5.5-fold). In 2003–2007, the highest rates in
Argentina were observed in Bahia Blanca, Cordoba, Santa Fe and
Mendoza (ASR: 42.4–45.3) while the lowest were in Chaco and
Tierra del Fuego (ASR: 24.6–24.4). In Brazil out of the 17 registries,
the highest incidence rates were seen in Goiania, Aracaju, Belo
Horizonte, and Salvador (ASR: 122.4–157.4) whereas the lowest
rates were in Teresina, Manaus and Campo Grande (28.5–35.6). In
Colombia, out of the 4 registries, Cali had the highest rates and
Pasto had the lowest (66.9 and 25.7, respectively). In Ecuador
(2 registries), prostate cancer incidence rates were higher in Quito
than in Cuenca (54.2 vs. 33.4). In Peru (2 registries), the highest rate
was in Arequipa and the lowest rate was in Lima (34.8 vs. 44.0)
(Fig. 1).
3.3. Age-speciﬁc rates
Prostate cancer incidence and mortality rates were strongly
related to age. In the most recent period evaluated, an average of
21% and 38% of cases were diagnosed in CSA men aged 70–74 andPeriod % of the population covered
1993–2007 0.8
1997–2006 8.0
1993–2008 2.2
1985–2007 100.0
Table 2
Age-standardized incidence and mortality rates (per 100,000) from prostate cancer in Central and South America, all ages.
Country Period INCIDENCE MORTALITY
Cases Crude Rate ASR (W) MV (%) DCO (%) Ranka Deaths Crude Rate ASR (W) Ranka
CENTRAL AMERICA
Belize 2003–2007 121 17.5 28.9 1
Costa Rica 1985–1989 880 12.2 18.4 83 0 2 579 8.0 10.6 4
2003–2007 4567 42.2 53.8 80 9 1 1508 13.8 14.8 2
Cubab 2004–2007 741 45.2 24.3 77 11 2 9026 39.9 24.1 2
El Salvadorb 1999–2003 210 1.6 2.0 80 0 2 811 5.7 6.8 3
Guatemala 2003–2007 2002 6.5 10.5 2
Mexicob 2006–2010 3779 22.1 28.9 100 0 1 25186 9.1 17.0 1
Nicaragua 2003–2007 746 5.5 9.4 1
Panama 2003–2007 1327 16.3 17.9 1
SOUTH AMERICA
Argentinab 2003–2007 5030 40.9 38.6 79 18 1 18948 20.0 15.0 3
Boliviab 2011 77 5.8 5.9 96 0 1
Brazilb 2003–2007 36524 65.5 91.4 89 6 1 51244 11.2 12.8 2
Chileb 2003–2007 1091 46.6 52.1 89 8 1 7630 18.9 16.9 3
Colombiab 2003–2007 4259 47.0 54.5 89 5 1 11337 10.7 14.9 3
Ecuadorb 2003–2007 1883 39.7 49.1 88 7 1 3247 9.6 11.4 2
French Guyanab 2003–2007 419 84.6 147.1 79 0 1
Paraguay 2003–2007 1275 8.6 12.4 2
Perub 2001–2005 2976 32.4 34.6 77 14 1 4814 7.1 9.7 2
Suriname 2003–2007 170 13.6 17.3 1
Uruguay 2005–2007 4287 89.2 59.8 82 13 1 1858 38.6 21.8 2
Venezuela 2003–2007 8859 13.2 18.7 1
ASR (W), age-standardized (World population) rate per 100,000; MV, microscopic veriﬁcation; DCO, death certiﬁcate only.
a Rank across cancer types, based on highest ASR excluding: All sites but C44 and All sites.
b Incidence rates were estimated using data from regional cancer registries.
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the age of 50 years. The mean age at diagnosis across CSA countries
ranged between 68 and 75 years (data not shown).
Incidence rates slowly increase below the age of 50 years and
rise rapidly thereafter, reaching rates over 100 (per 100,000) above
the age of 55 years and nearly 1000 per 100,000 in the 75 years
age group (Fig. 2). In general, prostate cancer mortality rates
followed a similar pattern. The highest mortality rates were
observed among older age groups, with rates reaching 100 (per
100,000) in above the age of 65 years to almost 1000 per 100,000 in
the 75 years age group (Fig. 2).
3.4. Time trends
The incidence of prostate cancer increased steadily, with
noticeable changes around the mid-1990s in Costa Rica and after
the year 2000 in Argentina, Brazil and Chile (Fig. 3). From 1997–
2008, the incidence increased, signiﬁcantly, on average by 4.8% per
year in Argentina, 3.8% per year in Costa Rica, 3.2% per year in Chile,
and 2.8% per year in Brazil (Fig. 4).
Mortality trends in prostate cancer all 4 countries analyzed
remained almost unchanged from 1997 to 2008 (Figs. 3 and 4).
Although, in Costa Rica, mortality steadily increased from 1985 to
the early-2000s but leveled of thereafter (Figs. 3 and 4).
3.5. Cancer control programmes
In response to the high burden of prostate cancer in the CSA
region, Brazil (2002), Colombia (2013), Costa Rica (2011), El
Salvador (2015), Mexico (2010), Nicaragua (2010), and Peru (2010)
have recently made prostate cancer a priority in their national
cancer plans and have developed guidelines for the detection,
diagnosis, treatment and follow-up of this malignancy [40–47].
The Ministries of Health from Ecuador, Panama, Paraguay, and
Venezuela have recently implemented national or regional
awareness campaigns for early detection of prostate cancer.In Argentina (2014), the “Programa Nacional de Consensos
Inter-Sociedades, Programa Argentino de Consensos de Enferme-
dades Oncológicas” developed a consensus guideline for detection,
diagnosis, and treatment of prostate cancer [48]. In Chile, the
public health system offers diagnoses and treatment for prostate
cancer and in 2014 an amendment to the Labor Code was passed,
allowing men over 50 to take half of a working day to undergo
prostate examinations for preventive medicine [49]. In Cuba, PSA
testing is recommended for symptomatic patients 45 years old
with family history of prostate cancer or for men 50 years or older
who request the test [50]. In 2007, Peru approved the Concerted
National Health Plan to reduce mortality from cancer, including
prostate cancer. In 2011, Peru began the process of implementation
of Universal Health Insurance (Act No. 29344); the Essential Health
Insurance Plan (D.S. 016-2009-S.A.) was approved as the minimum
health plan at the national level, which comprises healthcare
access for speciﬁc conditions, including prostate cancer. In 2012,
Peru proposed the Strategic Program for Cancer Prevention and
Control (Plan la Esperanza) in order to reduce morbidity and
mortality from cancer (including prostate cancer) [51]. The
Uruguayan government (2015) declared prostate cancer a public
heath priority and made available PSA and/or digital rectal
examination (DRE) examinations for men 40 years in health
centers issuing a health card or in centers of the Administration of
State Health Services [52]. None of the CSA countries support
organized population screening.
3.6. Early detection practices
Only a few studies for early detection of prostate cancer have
been conducted in CSA [29,53–59]. The main techniques used for
prostate cancer detection in the region involve measuring
prostate-speciﬁc antigens (PSA) in blood and/or DRE [60].
Conﬁrmation diagnosis of prostate cancer is done by using
transrectal ultrasound (TRUS) and TRUS-guided needle biopsy
[60].
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Fig. 1. Age-standardized incidence rates (ASR) from prostate cancer with corresponding 95% conﬁdence intervals (95% CI) in selected Central and South American cancer
registry populations for the most recent 5-year period, all ages.
S134 M.S. Sierra et al. / Cancer Epidemiology 44S (2016) S131–S140In Argentina, 2686 men 24–96 years old (mean age 63.4 years)
were screened with DRE and PSA and/or TRUS during the “Prostate
Week 2001” at the Hospital de Clinicas Jose de San Martin. Of the
576 with abnormal results, 285 underwent TRUS and 65 prostate
cancer cases were identiﬁed (detection rate 2.4%) [58].
In Brazil, the Barretos Cancer Hospital has a program that
offers screening for prostate cancer (PSA and DRE) as well as
screening for other common types of cancer (ie, skin, breast, andcervix) using mobile units in 231 municipalities from 6 states
[53]. From January 2004 to December 2007, 17,571 men 45 years
old were screened and 652 prostate cancer cases were identiﬁed,
mostly with localized disease (93.4%). Compliance with the
program was good, with 81% (2291/2841) of all men with
abnormal test results returning for further examination, and
72% (1647/2291) of them undergoing to biopsy examinations.
There were, however, differences in compliance rates by education,
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Fig. 2. Age-speciﬁc rates (per 100,000) from prostate cancer in Central and South America for the period 2003–2007, unless otherwise speciﬁed.
M.S. Sierra et al. / Cancer Epidemiology 44S (2016) S131–S140 S135with illiterate men (no formal education or unable to read and
write) having lower compliance with additional examinations than
literate men (any degree of formal education). Moreover,
illiterate men had worse prognostic variables than literate men:PSA > 10 ng/ml, locally advanced disease, and Gleason scores >7
[54]. This study also showed that literate men received PSA and/or
DRE more frequently than illiterate men prior to entering the study
[54].
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Fig. 3. Trends in prostate cancer incidence and mortality by country, all ages.
S136 M.S. Sierra et al. / Cancer Epidemiology 44S (2016) S131–S140In Chile in 1997, 1026 men underwent PSA screening and 11
(1.1%) cases were detected [56,57]. In a different study, 2197 men
underwent prostate cancer screening and 139 (6.4%) cases were
identiﬁed (as cited in [57]). In a study conducted in Talca (VII
Region of Chile) from 1997 to 1998, 327 men 40–59 years of age-6 -4 -2 
Brazil1 (1997-2006)
Chile1 (1997-2008)
Costa Rica (1997 -2007)
Argen tina1 (1998-2007)
*The  estim ated  annu al pe rc
1 Incide nce rates were e
Fig. 4. Estimated annual percent change (EAPC) in age-standardized incidence andunderwent PSA and DRE; 14 of them had abnormal results and 3 of
them had a well differentiated adenocarcinoma [59].
In Monterrey (Mexico) a screening program, using PSA and DRE
and including 973 men 40 years and older from 2004 to 2006,
showed that only 44% (55/125) of the men who had an abnormal
screening test underwent prostate biopsy and 27% (15/55) of these
were diagnosed with prostate cancer, mostly with high grade
lesions (based on Gleason scores 7) [61].
4. Discussion
Overall, prostate cancer is the most frequently diagnosed cancer
and the third leading cause of cancer deaths among males in the
CSA region. There was a remarkable variation in prostate cancer
incidence rates between and within CSA countries, probably due to
differences in diagnostic practices [3,4,13,62,63]. In contrast to the
striking variability in incidence from prostate cancer in CSA,
mortality showed less variation, probably because PSA testing has
a considerably greater effect on incidence than on mortality [64]. In
addition, geographic variations in incidence and mortality rates
could be explained by differences in registration, lack of adequate
health care access, advanced presentation at prostate cancer
diagnosis and treatment, as well as public awareness
[3,53,57,62,65–67].
In 2003–2007, Belize and Cuba had some of the highest
mortality rates in the world, only surpassed by Barbados (48.4).
Uruguay also had very high mortality rates from prostate cancer,
ranking 6th in the world after South Africa and Lithuania [68]. The
disproportionately high mortality rates from prostate cancer in the
CSA region could be a reﬂection of delayed diagnosis, as many
patients are diagnosed at an advanced stage [57,66]. Given the
uncertainties involved in assessing the impact of PSA testing on
prostate cancer incidence, mortality rates could be a more reliable
index of prostate cancer risk between CSA populations [69],1.6
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quality of death certiﬁcation [6,11,53].
The incidence and mortality of prostate cancer and their trends
as presented in this report are generally consistent with previous
reports from the region [3,70–72]. For example, the rapid increases
in the incidence of prostate cancer in Argentina, Brazil, Chile and
Costa Rica coincide with increases in prostate cancer reported in
other CSA regions in the last few decades, reﬂecting the increased
use of PSA testing, as well as changes in potential factors associated
with this malignancy (i.e. obesity and dietary fat) [3,31,70,71].
Interestingly, stable incidence rates have been reported in Pasto
(Colombia) [73]. Declines in mortality trends have been reported in
Argentina, Chile, and Costa Rica for 1980–2010, in Mexico since
2002, and in Panama from 2000 to 2009, suggesting improvements
in the management of the disease [6,71].
Studies have shown that increases in the incidence of prostate
cancer are mainly due to localized and moderately differentiated
tumors, probably a result of the introduction of better diagnostic
techniques [13,69,74]. Unfortunately, population-based cancer
registries in the region do not systematically collect information
on clinical stage or histological grade. Hence, we were unable to
disentangle early localized malignancies (likely detected through
PSA testing) from clinically advanced ones.
A review of geographic disparities in prostate cancer outcomes
in the United States, Canada, Mexico, the United Kingdom, Finland,
Netherlands, Australia and New Zealand revealed that, in urban
and afﬂuent areas, PSA testing was common, incidence and
survival were high, and healthcare access was greater, whereas in
rural and disadvantaged areas, prostate cancer was diagnosed
more frequently at advanced stages and mortality was high [5]. In
CSA, a cross-sectional study of 4183 men 60 years old revealed
that the frequency of prostate cancer examinations (DRE and/or
PSA) is lower in illiterate (0 years of education) men than in literate
men (12 years of education); the frequency of prostate cancer
examinations among illiterate men was the highest in Buenos Aires
(Argentina), Sao Paulo (Brazil), and Montevideo (Uruguay)
whereas it was the lowest in Havana-Cuba, Mexico City, and
Santiago-Chile (ranging from 32 to 48% vs. 13–20%, respectively)
[75]. A study conducted in Campinas Brazil during 2004–
2008 showed that men >40 years old and who were from lower
socioeconomic strata had higher mortality rates than men of
higher socioeconomic strata (RR = 1.38 [1.17, 1.59]); however,
differences in prostate cancer mortality were not observed in
men from middle socioeconomic strata, which could reﬂect lack of
access to preventive screening in poorer areas [76]. These ﬁndings
highlight the need to increase access to healthcare, in particular in
populations of lower socioeconomic status.
4.1. Determinants of prostate cancer
There are only a few risk factors known to increase the risk of
prostate cancer, such as age, family history and African-descen-
dant. It has been reported that men older than 65 years are more
40-times more likely to be diagnosed with prostate cancer than
younger men (<65 years) [2]. We observed the highest incidence
and mortality rates from prostate cancer were in elderly men as
compared to younger men. In fact, less than 1% of the cases were
diagnosed in men under the age of 50 years, a ﬁnding consistent
with previous studies [2]. Despite the high relative risk, familiar or
hereditary prostate cancer accounts for only 15% of all cases [77]
and therefore it is unlikely to completely explain the observed
variation in rates across CSA countries. Although we observed
elevated incidence rates in French Guyana and Brazil and high
mortality rates in Cuba and Belize, regions with a large percentage
of Black populations [78,79], the study of race and cancer risk in
most countries of the CSA region is very challenging becausecancer registries do not systematically record race/ethnicity and
because of the complex racial heterogeneity of the population
[26,80,81]. In CSA, racial categories based on the subject’s
perception of skin color are inﬂuenced by socioeconomic position
[80] which in turn could also reﬂect differences in health care
access and public awareness [53,57,62,65].
Recently, the World Cancer Research Fund (WCRF) published
new results which are based on a collaborative effort to pool
current knowledge on the causes of cancer. They reported that
body fatness and adult attained height were probably related to
advanced prostate cancer [82]. Obesity may promote the
development and progression of prostate cancer by several
mechanisms, including: inﬂammation [83], increased levels of
insulin-like growth factor-1 (IGF-1), sex hormones, and adipokines
[84,85]. The CSA region has undergone a rapid epidemiologic and
nutritional transition driven by its economic growth and prostate
cancer has concomitantly increased [31–34]. The nutritional
transition in Latin America is characterized by an increased
consumption of high fat and processed foods and a decline in the
consumption of fruits and vegetables [31,34,86,87]. Such nutri-
tional changes combined with physical inactivity and sedentary
lifestyle can induce increased body weight [86] and ultimately
increase the risk of advanced prostate cancer.
4.2. Regional actions for prostate cancer control and early detection
practices
Our review revealed that 11 out of 22 CSA countries have
recently taken action to reduce the large burden of prostate cancer
by creating and implementing guidelines for the detection,
diagnosis, treatment and follow-up of this disease [40–47]. The
review also indicated that PSA is not extensively used in CSA
[29,53–59] and organized screening programs are not recom-
mended. Although, Brazil initiated early detection activities in
2002, data from clinical trials suggest that PSA testing does not
impact on mortality within the ﬁrst 10-years of testing [88–90]. It
is expected that the incidence of prostate cancer will increase in
the future given recent early detection activities and increased
public awareness; however, the impact of such actions on prostate
cancer mortality (if any) remains to be elucidated.
4.3. Strengths and limitations
The present study has several strengths and limitations. We
aimed to describe the current burden of prostate cancer in CSA and
included the most readily available incidence data from 13 coun-
tries (48 cancer registries), more than the data published in the
latest volume of Cancer Incidence in Five Continents (CI5 X;
8 countries, 22 cancer registries) [91], and national mortality data
from 18 countries. However, data patterns must be interpreted
with caution because, for most countries, nationwide incidence
rates are represented by aggregated data from regional registries
which do not cover the entire country (except for Costa Rica and
Uruguay). Registrations may also differ in completeness and data
quality which could explain the strikingly low incidence rate of
prostate cancer observed in Bolivia and El Salvador. Despite visible
within country differences, the wide 95% conﬁdence intervals
shown in Fig. 1 in relation to the ASRs suggest that, the observed
variation may be due to chance alone. Furthermore, prostate
cancer rates may be impacted by differences in diagnostic practice
and death certiﬁcation procedures [8,13,62]. In some CSA
countries, the quality of death registration data may be considered
of medium or low quality [92].
The percentage of microscopically veriﬁed (MV) cases and the
proportion of cases identiﬁed by death certiﬁcate only (DCO) are
often used as quality indicators of cancer registry data (Table 2)
S138 M.S. Sierra et al. / Cancer Epidemiology 44S (2016) S131–S140[93,94]. In general, the percentage of MV cases in CSA registries
was lower than the MV% in the United States (77–89% vs. 97.5%,
respectively) and the percentage of DCO cases was higher in CSA
than in the United States (0–18% vs. 1%, respectively) [91]. In
Mexico and Bolivia 96–100% of the prostate cancer cases were MV
indicating an over-reliance on pathology laboratories as the source
of information [95].
Remarkable efforts in cancer registration have been undertaken
in CSA despite the limited resources allocated to most of these
registries. Improvements in coverage and quality of cancer
registrations in CSA are urgently needed as sustained cancer
registration will provide robust statistics on cancer burden in the
region to provide vital guidance for future cancer control activities.
Because of the projected increases in the burden of prostate cancer
in the region, continued monitoring of cancer incidence and death
remains a priority. Future epidemiological studies of prostate
cancer in the region should focus on understanding the reasons for
differences in treatment, stage at diagnosis, and early detection by
socioeconomic status. Given the strong association between
prostate cancer and race/ethnicity, well designed epidemiological
studies in such racial heterogeneous populations could help
elucidate the role of genetic and environmental factors in prostate
cancer risk.
5. Conclusion
Prostate cancer is the most common cancer diagnosis and one
of the ﬁve leading causes of cancer-related deaths among males in
the CSA region. There was a remarkable variation (up to 6-fold) in
prostate cancer incidence rates across countries. Mortality rates
varied by about 4-fold across CSA. The overall geographic and
temporal variation of prostate cancer rates observed in CSA may in
part reﬂect differences in diagnostic practices, registration, health
care access, treatment and death certiﬁcation, and public
awareness. The elevated rates observed in French Guyana, Brazil,
Cuba and Belize, regions with a large percentage of Black
populations, could in part be explained by the genetic susceptibil-
ity of this group. The extent to which other putative factors could
explain the observed geographic variation in prostate cancer rates
in the region is uncertain. Half of the countries in the region have
taken action to reduce the large burden of prostate cancer by
creating and implementing guidelines in diagnosis and care as well
as by creating awareness campaigns; thus it is expected that the
incidence of prostate cancer will increase in the near future.
However, the impact of such actions on prostate cancer mortality
(if any) remain to be elucidated. There is a need to increase access
to healthcare, in particular in populations of lower socioeconomic
status, which may result in earlier diagnoses and a more efﬁcient
use of healthcare resources, and a need to further understand the
root causes of the variation in incidence and mortality rates in the
region.
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